血管内皮生长因子受体KDR胞外区基因对裸鼠人膀胱癌生长的影响

目的研究血管内皮生长因子(VEGF)受体KDR胞外区基因对肿瘤新生血管的抑制作用.方法采用脂质体转染技术,将KDR胞外区基因的真核表达质粒pcDNA3.1/KDRn7转入人膀胱癌EJ细胞,用G418筛选得到稳定表达目的蛋白的细胞克隆,经固相结合实验筛选得到表达与VEGF特异结合的目的蛋白的细胞克隆,阳性细胞克隆进行了RT-PCR鉴定.结果鸡胚测活表明,EJ细胞表达rKDRn7的能抑制鸡胚绒毛尿囊膜的血管形成;表达rKDRn7的EJ细胞株对裸鼠人膀胱癌生长及血管生成明显抑制,实验组的微血管密度(MVD)为12±4,阴性对照组62±11.结论阻断VEGF/KDR信号传导途径能够抑制肿瘤新生血管的形成,延缓肿瘤的生长速度.     

IFN-α抑制肿瘤血管形成的实验研究

目的:探讨干扰素α(IFN-α)的抗肿瘤血管形成作用机制.方法:采用MTT法检测不同浓度IFN-α对体外培养的人脐静脉内皮细胞增殖的影响;检测不同剂量IFN-α对鸡胚绒毛尿囊膜新生血管形成的影响.结果:IFN-α对血管内皮细胞增殖有直接抑制作用;而且对鸡胚绒毛尿囊膜新生血管形成也有抑制作用.结论:提示IFN-α可通过直接抑制血管内皮细胞增殖而发挥抗血管形成作用.     

三氧化二砷抗肝癌血管新生作用

目的:探讨三氧化二砷(As2O3)注射液抗肝癌血管新生的作用及其相关机制。方法:采用MTT法、透射电镜观察、免疫组化、鸡胚尿囊膜(CAM)血管形成实验等方法,观察As2O3注射液对人肝癌细胞株SMMC-7721和人脐静脉内皮细胞ECV304生长、超微结构、血管内皮生长因子(VEGF)和表皮生长因子受体(EGFR)蛋白表达以及对CAM血管形成的影响。结果:As2O3能显著抑制人肝癌细胞SMMC-7721和人脐静脉内皮细胞ECV304生长,用药后诱导其出现了典型的细胞凋亡超微结构改变;As2O3对SMMC-7721细胞和ECV304细胞VEGF、EGFR的表达均有抑制作用;As2O3能抑制CAM血管形成。结论:As2O3注射液具有显著抗肝癌血管新生作用,其机制与抑制血管内皮细胞生长、诱导血管内皮细胞凋亡、调控肿瘤血管新生相关因子VEGF和EGFR的表达密切相关。     

抗VEGF抗体对骨肉瘤OS-732细胞血管生成及其肿瘤细胞增殖、凋亡的影响

目的：探讨阻断血管内皮生长因子（Vascular endothelial growth factor,VEGF)的血管生成作用对骨肉瘤OS-732细胞及血管内皮细胞增殖、凋亡的影响。方法：应用鸡胚绒毛尿囊膜（CAM）模型,通过解剖显微镜血管计数,光镜HE染色,原位末端标记及PC-NA免疫组化检测观察VEGF抗体对骨肉瘤血管生成及肿瘤增殖,凋亡状态的影响。结果：VEGF抗体组肿瘤区血管数目及瘤细胞数显著低于PBS对照组,肿瘤细胞凋亡指数显著高于PBS对照组,增殖指数两组差异不明显,同时VEGF抗体组凋亡的微血管内皮细胞增多,增殖期微血管内皮细胞少见。结论：VEGF抗体能显著抑制骨肉瘤OS-732血管生成,抑制内皮细胞增殖,促进内皮细胞凋亡,可能是VEGF抗体发挥抗血管生成作用的途径之一,并可能通过抑制血管形成而促进肿瘤细胞凋亡,最终达到抑制瘤细胞生长的作用。     

血管内皮生长因子家族及其受体与肿瘤血管新生

血管新生在肿瘤的生长及转移过程中发挥着极为重要的作用,而血管内皮生长因子(VEGF)是肿瘤血管新生过程中重要的促进因子,其能够与血管内皮细胞上相应的受体结合刺激内皮细胞增殖、迁移,进而促进肿瘤血管新生。阻断VEGF与其相应的受体结合可以抑制肿瘤的生长。目前研究以VEGF及其受体为靶点的血管新生抑制剂如单克隆抗体、多靶点酪氨酸激酶抑制剂以及小干扰RNA等给肿瘤的治疗带来了新希望。     

hVEGF siRNA抑制A549细胞在裸鼠移植瘤的早期生长及血管新生

目的:探讨血管内皮细胞生长因子(human vascular endothelial growth factor,hVEGF)的小干扰RNA(small interfering RNA,siRNA)对A549细胞裸鼠移植肿瘤生长以及对鸡胚尿囊膜(chorioallantoic membrane,CAM)上诱导新生血管的影响.方法:分别构建3个表达不同特异性hVEGF siRNA序列的质粒载体,与表达无关序列siRNA质粒载体分别转染A549细胞,用ELISA与realtime RT-PCR选出抑制hVEGF效果最佳的hVEGF siRNA质粒.G418筛选出稳定表达抑制效果最佳的hVEGF siRNA和表达无关序列siRNA的A549细胞,与未转染的A549细胞分别注射于裸鼠皮下,观察3组细胞在裸鼠皮下成瘤及肿瘤生长的速度.鸡胚尿囊实验:孵育至第9天的白皮受精种蛋随机分为4组,分别在鸡胚尿囊膜表面加未培养过A549细胞的DMEM培养液(阴性对照组),未转染的A549细胞培养上清液(阳性对照组),转染hVEGF siRNA的A549细胞培养上清液(hVEGF siRNA组),转染无关序列siRNA的A549细胞培养上清液(无关序列siRNA组),继续孵育48 h,取固定后的鸡胚绒毛尿囊膜于显微镜下计数血管分支点和血管分支长度.结果:hVEGF siRNA使A549细胞表达mRNA水平最大下降70%,分泌hVEGF水平最大下降48%.在裸鼠移植瘤模型中,hVEGF siRNA组比无关序列siRNA组肿瘤平均体积减少58%,肿瘤生长到50 mm3的平均时间延迟5.4 d,移植肿瘤组织匀浆hVEGF含量降低54%;而肿瘤的倍增时间与肿瘤生长速率差异不显著.在鸡胚尿囊膜实验中,阴性对照组加样液的hVEGF含量为0,hVEGF siRNA组加样液的hVEGF含量约占无关序列siRNA组和阳性对照组的40%～44%;血管分支点计数,hVEGF siRNA组,无关序列siRNA组与阳性对照组比阴性对照组增加45%～55%;血管分支总长度hVEGF siRNA组比阴性对照组增加约53%,无关序列siRNA组和阳性对照组比阴性对照组分别增加约97%及99%.CAM血管图上与阴性对照组比较VEGF siRNA组可见增多的血管分支,阳性对照组和无关序列siRNA组上还可以见血管分支增粗、增长.结论:构建并证实质粒介导的hVEGF siRNA能抑制A549细胞分泌VEGF,从而抑制A549细胞诱导鸡胚尿囊膜的血管新生.在裸鼠移植瘤模型中,hVEGF siRNA能抑制肿瘤早期生长,对肿瘤后期的生长速率无显著抑制.     

海参皂苷Echinoside A通过MMP-9信号通路抑制肿瘤转移

从富含海参皂苷的革皮氏海参中分离纯化出Echinoside A（EA）,并研究了其抗肿瘤细胞转移活性及其作用机制。通过MTT法检测了EA对肿瘤细胞(HepG2)和人脐静脉内皮细胞生长的影响;采用细胞黏附实验、划痕愈合实验和Transwell小室侵袭模型研究了EA对肿瘤细胞黏附、迁移和侵袭能力的影响;采用体外小管形成实验和鸡胚绒毛尿囊膜(CAM )血管新生模型研究了EA对血管新生的影响。实验结果表明：EA能显著抑制肿瘤细胞和内皮细胞的增殖,抑制肿瘤细胞的迁移、侵袭和黏附能力,显著抑制 CAM 新生血管生成作用。免疫细胞化学和Western-blotting实验表明,EA能显著下调MMP-9和VEGF的蛋白表达,提高TIMP-1的表达,但是对NF-κB p65的表达无显著性影响;提示EA具有显著的抑制肿瘤转移作用,其作用机制可能是通过MMP-9信号通路并进一步抑制血管内皮生长因子的蛋白表达实现。     

CCR5亲和短肽抗肿瘤活性研究

目的 探讨趋化因子受体CCR5亲和短肽（AFDWTFVPSLIL）对肿瘤生成作用的影响。方法 通过MTT实验、细胞凋亡实验检测短肽对血管内皮细胞生长的影响，通过鸡胚绒毛尿囊膜（CAM）实验检测短肽对血管生成的影响，通过体内抑瘤实验检测短肽对实体瘤生长的作用。结果 短肽能通过诱导人脐静脉血管内皮细胞的凋亡来抑制内皮细胞的生长；并能抑制CAM膜的血管生成。短肽也能在体内抑制小鼠B16黑色素瘤的生长活性，其抑瘤率达68．6％。结论 初步证明短肽具有抗肿瘤生成作用，且这种作用可能是通过抑制肿瘤的血管生成来实现。     

重组人p43蛋白抗血管生成活性及其机制

为了研究重组人p43(YS-1)蛋白对血管生成的影响及其机制,并考察其对肺癌实体瘤的抑制作用。采用内皮细胞增殖实验、细胞迁移实验、管腔形成实验、大鼠动脉环体外实验、鸡胚尿囊膜体内实验考察YS-1的抗血管生成作用;采用Western印迹法检测细胞内磷酸化MEK1/2、Akt蛋白质的表达;选用人肺腺癌A-549裸小鼠移植瘤模型检测YS-1的体内抗肿瘤活性。结果发现,YS-1能明显抑制内皮细胞迁移和管腔形成,可以抑制体外培养的大鼠动脉环微血管样结构及鸡胚尿囊膜血管,YS-1可以明显抑制血管内皮生长因子（VEGF）诱导的内皮细胞中VEGFR2及下游MEK1/2及Akt的磷酸化,YS-1高剂量(10mg/kg)能显著抑制肺癌A549移植瘤的生长。研究结果表明：YS-1能抑制人肺腺癌A-549裸鼠移植瘤的生长,其作用机制可能跟抑制VEGF引起的VEGFR2活化及信号转导而影响血管生成有关。     

Citrostatin的构建与活性分析

目的:本研究拟通过人工化学合成技术将2个不同机制发挥抗癌作用的小肽结合起来,产生一个融合肽Citrostatin,并研究其生物学活性,以期获得具有双重抗肿瘤功能的抗肿瘤肽.方法:化学合成Citrostatin并经HPLC分离纯化,通过内皮细胞杀伤实验、细胞毒活性分析、体外管状结构生成抑制实验,以及鸡胚绒毛尿囊膜血管生成抑制实验分析Citrostatin的生物学活性.结果:Citrostatin可明显抑制内皮细胞ECV304的增殖(ED50为6.2 μg/ml),有效杀伤肿瘤细胞1990及NCI-H640细胞(ED50分别为50 μg/ml、16 μg/ml),并明显抑制体外管状结构生成及鸡胚绒毛尿囊膜血管的生成.结论:本研究成功构建并合成了抗肿瘤融合48肽Citrostatin,研究表明该融合肽同时具有抑制肿瘤组织新生血管形成和直接杀伤肿瘤的双重活性.     

益气养阴方抗血管生成作用及对肿瘤细胞VEGF及MMP2表达的影响

目的观察益气养阴方抗血管生成作用及对肿瘤细胞血管内皮生长因子（vascular endothelial growth factor,VEGF）和基质金属蛋白酶（matrix metalloproteinase,MMP）2表达的效应。方法制备接种肿瘤细胞的绒毛尿囊膜（chorioallantoic membrane,CAM）模型,采用血清药理学方法制备益气养阴方含药血清。观察含药血清对肿瘤细胞诱导CAM血管生成的影响,并与9．0g／L氯化钠注射液（normal saline,NS）血清组对照。另外,用U14子宫颈癌细胞悬液经肌肉接种小鼠,观察小鼠实体瘤质量、抑瘤率、肺部转移率、肺部转移瘤生长情况。应用免疫组织化学及其组织形态学定量分析方法对VEGF和MMP2在肿瘤细胞中的表达进行研究。结果益气养阴方含药血清可抑制肿瘤细胞诱导CAM血管生成,与NS组比较差异具有显著性。益气养阴方组肺部转移结节较模型组明显减少,VEGF和MMP2的表达均明显低于对照组,差异有显著性。结论益气养阴方对肿瘤血管形成有明显抑制作用,降低VEGF和MMP2的表达可能是其抑制肿瘤血管形成的主要机制之一。     

Expression of Human Vascular Endothelial Growth Factor Receptor Flt—1 Extracellular Domain 1—3 Loop cDNA in Pichia pastoris,Purification of the Expressed Product and Detection of Its Biological Acti

Objective:to express human vascular endothelial growth factor receptor Flt-1 extracellular domain 1-3 loop cDNA in Pichia.pastroris,and to purify the expressed product and detect its biological activity.Methods:By inserting human Flt-1(1-3 loop)cDNA coding 316 amino acid residues into Pichia pastoris expression vector pPIC9K containing AOX1 promoter and the sequences of α secreting signal peptides,a recombinant expression plasmid pPIC9K/Flt-1(1-3) was constructed and transformed to yeast host strain GS115,then His^ Muts phenotype transformant was screened out and cultured in flasks,and Flt-1(1-3) was expressed under the induction of 1% methanol.Results SDS-PAGE showed that after being induced with 1% methanol for 4d ,the expressed product existed in supernatant in the form of soluble molecule and contained 60% of total protein expresses.Western blot showed good antigenicity and specificity of expressed product.After being purifed by CM-Sepharose FF and Sephacry1 S-100 chromatography,the purity of the expressed product reached obove 90%,Biological assay proved that the expressed product could bind to hVEGF165 and inhibit the proliferation of HUVEC stimulated by hVEGF165.Conclusion:Human vascular endothelial growth factor receptor Flt-1 exracellular domian 1-3 loop was successfully expressed.The study lays f foundation for further application of the expressed product in the troduct in the treatment of vasoformation related diseases,such as tumor and diabetic retinopathy.     

Brain hyaluronan binding protein inhibits tumor growth

Background Great efforts have been made to search for the angiogenic inhibitors in avascular tissues. Several proteins isolated from cartilage have been proved to have anti-angiogenic or antitumour effects. Because cartilage contains a great amount of hyaluronic acid (HA) oligosaccharides and abundant HA binding proteins ( HABP), therefore, we speculated that HABP might be one of the factors regulating vascularization in cartilage or anti-angiogenesis in tumours. The purpose of this research was to evaluale the effects of hyaluronan binding protein on inhibiting tumour growth both in vivo and vitro. Methods A unique protein termed human brain hyaluronan (HA) binding protein (b-HABP) was cloned from human brain cDNA library. MDA-435 human breast cancer cell line was chosen as a transfectant. The in vitro underlying mechanisms were investigated by determining the possibilities of MDA-435/b-HABP colony formation on soft agar, the effects of the transfectant on the proliferation of endothelial cells and the expression levels of caspase 3 and FasL from MDA-435/b-HABP. The in vivo study included tumour growth on the chorioallantoic membrane (CAM) of chicken embryos and nudemice. Results Colony formation assay revealed that the colonies formed by MDA-435/b-HABP were greatly reduced compared to mock transfectants. The conditioned media from MDA-435/b-HABP inhibited the growth of endothelial cells in culture. Caspase 3 and FasL expressions were induced by MDA-435/b-HABP. The size of tumours of MDA-435/b-HABP in both CAM and nude mice was much smaller than that of MDA-435 alone. Conclusions Human brain hyaluronan binding protein (b-HABP) may represent a new kind of naturally existing anti-tumour substance. This brain-derived glycoprotein may block tumour growth by inducing apoptosis of cancer cells or by decreasing angiogenesis in tumour tissue via inhibiting proliferation of endothelial cells.     

外源p53基因和抗血管生成小肽F56联合对小鼠乳腺癌移植瘤生长和转移的抑制作用

目的:观察腺病毒介导的野生型p53基因联合抗血管生成小肽 F56对乳腺癌移植瘤及其肺转移灶的抑制作用.方法:将人乳腺癌BICR-H1细胞接种于裸鼠或NOD/SCID小鼠乳垫内.成瘤后,裸鼠随机分成Adp53+F56组、 Adp53组、F56组和空白对照组,NOD/SCID小鼠则随机分成Adp53+F56组、Adp53组、F56组、Adlacz组和空白对照组,分别采用腺病毒p53、F56或二者联合治疗,以小肽溶剂作对照,NOD/SCID小鼠还加用腺病毒空载体(Adlacz)作对照.观察裸鼠移植肿瘤体积、组织病理学改变,用免疫组织化学方法检测肿瘤p53、血管内皮生长因子(vascular endothelial growth factor, VEGF)的表达及微血管密度(microrascular density, MVD);观察NOD/SCID小鼠移植瘤的肺转移情况.结果:p53基因、F56及二者联合治疗均能明显抑制裸鼠移植瘤生长,但以联合治疗组最显著,Adp53+F56组、Adp53组、F56组和空白对照组肿瘤最终的相对生长体积分别为2.47、4.37、4.69和12.49 ;免疫组织化学检测发现,Adp53+F56组和Adp53组肿瘤内p53表达增高,P53阳性率分别增高了9.4%、6.3%,但与空白对照组比较,差异无统计学意义(P=0.693);Adp53+F56组、Adp53组、F56组VEGF表达下降, VEGF阳性率分别下降21.9%、9.4%和3.1%,但与空白对照组比较,差异亦无统计学意义(P=0.284);Adp53+F56组、Adp53组、F56组MVD分别为14.50±2.54、16.28±3.44和18.06±7.66,与空白对照组(24.93±6.53)比较,差异有统计学意义(P=0.000), 且Adp53+F56组、Adp53组、F56组瘤内出现坏死,并以Adp53+F56组最为明显.NOD/SCID小鼠Adp53+F56组、Adp53组、F56组肺转移灶平均数目分别为1.143±0.378, 2.750±0.886, 3.375±0.518,较Adlacz组(5.000±0.816)和空白对照组(5.670±0.817 )都显著减少(P=0.000),尤以Adp53+F56组最少.结论:p53基因联合抗肿瘤血管生成小肽F56可显著抑制肿瘤的生长和转移.p53基因影响肿瘤生长与转移的因素之一可能与p53对VEGF的抑制作用有一定关系.     

血管内皮生长因子及其受体Flt-1在乳腺癌中的表达及意义

目的　试图揭示血管内皮生长因子 (VEGF)及其受体 (Flt 1)在乳腺癌组织中的表达规律 ,探讨其与血管生成和肿瘤浸润、转移等生物学行为的关系。方法　应用原位杂交和免疫组织化学技术 ,检测 4 8例乳腺癌组织中VEGF和Flt 1的mRNA和蛋白表达特性。结果　乳腺癌细胞高表达VEGFmRNA和蛋白 ,阳性率分别为 75 %、70 8% ,而血管内皮细胞几乎不表达 ;血管内皮细胞主要表达受体Flt 1mRNA和蛋白 ,阳性血管数分别为 2 6个 / 0 72mm2 ± 12个 / 0 72mm2 、2 4个 / 0 72mm2 ± 12个 / 0 72mm2 ,而少数癌细胞有少量表达 ;VEGF和Flt 1高表达组血管密度明显高于低表达组 ;VEGF和Flt 1表达与组织学分级和淋巴结转移密切相关。结论　VEGF以旁分泌途径促进乳腺癌血管形成 ,并参与肿瘤浸润和淋巴道转移过程 ,检测VEGF和Flt 1表达可做为判定乳腺癌血管生成、恶性度以及浸润转移等生物学行为的可靠指标。     

血小板第四因子抗肿瘤血管生成研究进展

血小板因子4是由活化的血小板α颗粒分泌的趋化因子,属于CXC4家族,具有抗肿瘤血管生成的活性,属于内源性的血管生成抑制因子。其可以通过多种机制抑制肿瘤的血管生成,如抑制血管内皮细胞生长因子、碱性成纤维细胞生长因子介导的血管内皮的增殖;削弱p21的下调,抑制内皮细胞分裂、增殖;抑制基质金属蛋白酶的表达,防止新生血管向周围组织的蔓延等,从而有效抑制肿瘤的新生血管形成。     

基于VEGFR靶点的小分子肿瘤靶向抑制肽的99Tcm标记及鉴定

目的 探讨基于血管内皮生长因子受体( vascular endothelial growth factor receptor,VEGFR)靶点的小分子肿瘤靶向抑制肽理想的放射性核素99 Tcm标记方法.方法 多肽QKRKRKKSRKKH、RKRKRKKSRYIVLS分别经双功能螯合剂S-acetyl-MAG3、GA(D)GG、HYNIC修饰后进行放射性核素99 Tcm标记,HPLC及纸层析法鉴定其标记率及放化纯度,3 H-TdR参入实验鉴定其抑制细胞增殖的能力,体外受体竞争结合实验鉴定其受体结合活性.结果 以HYNIC为双功能螯合剂,这2条多肽的99 Tcm标记率分别为(94.13±1.77)％、(93.79±3.53)％,明显高于S-acetyl-MAG3、GA(D) GG修饰多肽的标记率.经HYNIC修饰后的多肽对肿瘤细胞A549增殖的抑制率约为(32.86±3.36)％、(61.50±4.50)％,与修饰前无明显变化(P＞0.05);多肽标记后仍保持了良好的VEGFR结合活性,室温下放置24 h后,放化纯度仍高达90％左右.结论 以HYNIC为双功能螯合剂,以TPPTS为协同配体及还原剂,多肽QKRKRKKSRKKH、RKRKRKKSRYIVLS的99Tcm标记率高,且仍具有良好的抑制肿瘤细胞增殖的能力和VEGFR结合活性.     

Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial ceils

Background Tumstatin is a recently developed endogenous vascular endothelial growth inhibitor that can be applied as an anti-angiogenesis and antineoplastic agent.The study aimed to design and synthesize the small molecular angiogenesis inhibition-related peptide (peptide 21),to replicate the structural and functional features of the active zone of angiogenesis inhibition using tumstatin and to prove that synthesized peptide 21 has a similar activity:specifically inhibiting tumor angiogenesis like tumstatin.Methods Peptide 21 was designed and synthesized using biological engineering technology.To determine its biological action,the human umbilical vein endothelial cell line ECV304,the human ovarian cancer cell line SKOV-3 and the mouse embryo-derived NIH3T3 fibroblasts were used in in vitro experiments to determine the effect of peptide 21 on proliferation of the three cell lines using the MTT test and growth curves.Transmission electron microscopy (TEM) and flow cytometry (FCM) were applied to analyze the peptide 21-induced apoptosis of the three cell lines qualitatively and quantitatively.In animal experiments,tumor models in nude mice subcutaneously grafted with SKOV-3 were used to observe the effects of peptide 21 on tumor weight,size and microvessel density (MVD).To initially investigate the role of peptide 21,the effect of peptide 21 on the expression of vascular endothelial growth factors (VEGFs) by tumor tissue was semi-quantitatively analyzed.Results The in vitro MTT test and growth curves all indicated that cloned peptide 21 could specifically inhibit ECV304 proliferation in a dose-dependent manner (P ＜0.01);TEM and FCM showed that peptide 21 could specifically induce ECV304 apoptosis (P ＜0.01).Results of in vivo experiments showed that tumors in the peptide 21 group grew more slowly.The weight and size of the tumors after 21 days of treatment were smaller than those in the control group (P ＜0.05),with a mean tumor inhibition rate of 67.86%;MVD of the tumor tissue in the peptide 21 group was significantly lower than in the control group (P＜0.05);the number of cells positive for VEGF in the peptide 21 group was significantly fewer than in the control group (P ＜0.01).Conclusions Similar to the activity of tumstatin in specifically inhibiting tumor angiogenesis,peptide 21 may specifically inhibit tumor endothelial cell proliferation and induce their apoptosis,thereby suppressing tumor angiogenesis and indirectly inhibit the growth,infiltration and metastasis of tumors.Peptide 21 may exert its effect through down-regulating the VEGF expression of tumor cells and vascular endothelial cells.     

氟尿嘧啶抗血管生成作用的实验研究

目的：探讨氟尿嘧啶(5-FU)的抗血管生成作用。方法：以人脐静脉内皮细胞(HUVEC)原代培养模型，MTT法测定5-FU对HUVEC增殖的影响；采用鸡胚尿囊膜血管形成模型(CAM模型)，观察5-FU对鸡胚尿囊膜新生血管的抑制作用。结果：5-FU在非细胞毒浓度下可在体外抑制HUVEC的增殖，在体内抑制鸡胚尿囊膜新生血管形成。结论：5-FU在非细胞毒浓度下具有抗血管生成作用。     

胎盘生长因子及其受体在妇产科领域的研究进展

胎盘生长因子(PLGF)是血管内皮生长因子(VEGF)家族成员之一。它通过与其受体VEGFR-1(Flt-1)结合发挥生物学作用,促进新生血管形成,参与了肿瘤,炎症等病理生理过程。研究表明PLGF及其受体在妊娠并发症、子宫内膜异位症和肿瘤中起着重要作用。